首页> 外文期刊>The annals of pharmacotherapy >Impact of Medication Reconciliation and Review on Clinical Outcomes
【24h】

Impact of Medication Reconciliation and Review on Clinical Outcomes

机译:药物和解对临床结果的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To examine the evidence regarding the effectiveness of medication reconciliation and review and to improve clinical outcomes in hospitals, the community, and aged care facilities. Data Source: This systematic review was undertaken in concordance with the PRISMA statement. Electronic databases, including MEDLINE, PsycINFO, EMBASE, and CINAHL were searched for relevant articles published between January 2000 and March 2014. Study Selection and Data Extraction: Randomized and nonrandomized studies rating the severity of medication discrepancies and medication-related problems identified during medication reconciliation and/or review were considered for inclusion. Data were extracted independently by 2 authors using a data collection form. Data Synthesis: Of the 5292 articles identified, 83 articles met the inclusion criteria. Medication reconciliation identified unintentional medication discrepancies in 3.4% to 98.2% of patients. There is limited evidence of the potential of these discrepancies to cause harm. Medication reviews identified medication-related problems or possible adverse drug reactions in 17.2% to 94.0% of patients. The studies reported conflicting findings regarding the impact of medication review on length of stays, readmissions, and mortality. Conclusions: The evidence demonstrates that medication reconciliation has the potential to identify many medication discrepancies and reduce potential harm, but the impact on clinical outcomes is less clear. Similarly, medication review can detect medication-related problems in many patients, but evidence of clinical impact is scant. Overall, there is limited evidence that medication reconciliation and medication review processes, as currently performed, significantly improve clinical outcomes, such as reductions in hospital readmissions.
机译:目的:审查有关药物和解和审查有效性的证据,并改善医院,社区和老年护理设施的临床结果。数据来源:此系统审查是与PRISMA陈述的一致性进行的。在2014年1月至2014年3月出版的相关文章中搜索了电子数据库,包括Medline,Psycinfo,Embase和Cinahl。学习选择和数据提取:随机和非扫描研究评估药物和解中鉴定的药物差异和药物相关问题的严重程度和/或审查被认为是包含的。使用数据收集表单独立提取数据。数据合成:在5292篇文章中确定,83条符合纳入标准。药物和解在3.4%至98.2%的患者中确定了无意的药物差异。有限的证据证据了这些差异造成伤害的潜力。药物评论鉴定了与患者的17.2%至94.0%的药物相关问题或可能的不良药物反应。研究报告了有关药物审查对留下长度,入伍和死亡的影响的矛盾的调查结果。结论:证据表明,药物和解有可能识别许多药物差异并降低潜在的伤害,但对临床结果的影响不太明确。同样,药物审查可以检测许多患者中的药物相关问题,但临床影响的证据是狭窄的。总体而言,目前进行的药物和解和药物审查过程有限的证据表明药物和解和药物调查过程显着改善了临床结果,例如医院入院的减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号